🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: DPI Inhaler Therapy

Found 109 matching trials

Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

Batefenterol is a novel bifunctional molecule that combines muscarinic anta...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-11-06

Trial ID

NCT02570165

Treatments Being Tested

Batefenterol Umeclidinium/ Vilanterol Placebo

To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)

PHASE1

This will be a randomized, double-blind, single-dose, three-period balanced...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-11-08

Trial ID

NCT01725685

Treatments Being Tested

FF 400 mcg UMEC 500 mcg FF/UMEC 400/500 mcg

Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation

PHASE1

This is an open-label, five- period, cross-over, randomized, single dose, s...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-10-28

Trial ID

NCT02218723

Treatments Being Tested

FF UD-DPI FF ELLIPTA DPI

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

PHASE1

This study will evaluate the pharmacokinetics of FF, UMEC and VI administer...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-07-15

Trial ID

NCT01894386

Treatments Being Tested

FF 400 mcg UMEC 500 mcg UMEC 250 mcg VI 100 mcg

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

This randomized, cross over study aims to find out the benefits of deliveri...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-09-20

Trial ID

NCT03227445

Treatments Being Tested

ELLIPTA placebo DPI DISKUS placebo DPI HandiHaler placebo DPI Inhaler preference questionnaires

Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy

PHASE2

The purpose of this study is to evaluate the efficacy and safety of CHF6001...

Status

Terminated

Location

Site 032020 - Instituto Especialidades de la Salud Rosario - Clinica del Torax

Start Date

2023-11-26

Trial ID

NCT06029595

Treatments Being Tested

Experimental: CHF6001 3200 μg Placebo Comparator: CHF6001 Placebo

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

This is a multicenter, randomized, double-blind, placebo-controlled, 2-peri...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-01-23

Trial ID

NCT02275052

Treatments Being Tested

UMEC/VI DPI Placebo DPI Albuterol/salbutamol MDI

Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease

PHASE1

GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonis...

Status

Completed

Location

GSK Investigational Site

Start Date

2005-12-12

Trial ID

NCT00279019

Treatments Being Tested

GSK233705 Tiotropium Placebo

A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001

PHASE2

The purpose of this study is to evaluate the amount of the study drug, CHF6...

Status

Completed

Location

Medical Centre Comac Medical Ltd.

Start Date

2025-03-28

Trial ID

NCT06900816

Treatments Being Tested

CHF 6001 CHF 6001

Previous Next